• Compound Map provides Foundation for SARS-CoV-2 Inhibitors Discovery
    Frank von Delft, Principle Beamline Scientist (Credit: Diamond Light Source)
  • Alice Douangamath Senior Beamline Scientist (Credit: Diamond Light Source)
  • Jose Brandao-Neto Senior Beamline Scientist (Credit: Diamond Light Source)

News & Views

Compound Map provides Foundation for SARS-CoV-2 Inhibitors Discovery

Apr 15 2021

A new international study(1) has provided a template for how to develop directly-acting antivirals with novel modes of action, that would combat COVID-19 by suppressing the SARS-CoV-2 viral infection. The study focused on the macrodomain part of the Nsp3 gene product that SARS-CoV-2 uses to suppress the host cell’s natural antiviral response. This part of the virus’s machinery, also known as Mac1, is essential for its reproduction: previous studies have shown that viruses that lack it cannot replicate in human cells, suggesting that blocking it with a drug would have the same effect. 

The study involved a crystallographic fragment screen of the Nsp3 Mac1 protein by an open science collaboration between researchers from the University of Oxford, the XChem platform at Diamond Light Source, the UK’s national synchrotron and researchers from the QCRG Structural Biology Consortium at the University of California San Francisco.  The international effort discovered 234 fragment compounds that directly bind to sites of interest on the surface of the protein, and map out chemical motifs and protein-compound interactions that researchers and pharmaceutical companies can draw on to design compounds that could be developed into antiviral drugs.  This work is thus foundational for preparing for future pandemics.  

“Robustly identifying this kind of chemical matter for promising and tractable targets like Nsp3 is a first step in rational drug discovery.  This is always a long journey fraught with difficulty and failure, but the battery of new structural biology methods that we combined in this study, including fragment screening at Diamond and computational docking at UCSF, are helping to change drug discovery and make it easier to find effective drug candidates,” commented Principal Beamline Scientist, Frank von Delft. 

Fragment screening is an approach for identifying building blocks of the future drug molecule, observing how they interact with the protein under study, contextualizing those interactions, and providing starting points for molecules that directly influence the biology of the protein. This method significantly reduces the number of compounds that need to be screened to find one that really binds, while still informing a broad range of potential molecules.  Doing the experiment by structural biology, as implemented at the XChem platform, yields this information directly in 3D, greatly accelerating up the design process and ensuring a far more cost-effective overall experiment.  

The UCSF collaborators also used another innovative drug discovery technique, Computational Docking.  This deploys computer models and simulations to assess the likely interactions of virtual molecules for favourable interactions with Mac1 and their promise as starting points for drug discovery. The team identified 60 candidates from a virtual library of 20 million molecules, which were then experimentally tested using X-ray crystallography, yielding 20 good hits.   

“This is a significantly higher-than-random hit rate, validating the new specific docking methodologies developed by our UCSF colleagues.  The high quality structural data of Mac1 that we obtained by X-ray crystallography was essential, but the validation of the approach means that in future, we have additional power for exploring compounds that are not physically available. Overall, this work not only accelerates our ability to validate whether targeting NSP3 Mac1 is an effective way to develop antivirals;  it also is hugely valuable in improving the template of methodologies for future inhibitor discovery and development throughout the community of drug discovery,” concluded Frank von Delft. 

Science Advances Paper: 'Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking' advances.sciencemag.org/cgi/content/full/7/16/eabf8711/DC1. Published 14 April 2021  10.1126/sciadv.abf8711 

Authors: Marion Schuller, Galen J. Corey, Stefan Gahbauer, Daren Fearon, Taiasean Wu, Roberto Efraín Díaz, Iris D. Young, Luan Carvalho Martins, Dominique H. Smith, Ursula Schulze-Gahmen, Tristan W. Owens, Ishan Deshpande, Gregory E. Merz, Aye C. Thwin, Justin T. Biel, Jessica K. Peters, Michelle Moritz, Nadia Herrera, Huong T. Kratochvil, QCRG Structural Biology Consortium, Anthony Aimon, James M. Bennett, Jose Brandao Neto, Aina E. Cohen, Alexandre Dias, Alice Douangamath, Louise Dunnett, Oleg Fedorov, Matteo P. Ferla, Martin R. Fuchs, Tyler J. Gorrie-Stone, James M. Holton, Michael G. Johnson, Tobias Krojer, George Meigs, Ailsa J. Powell, Johannes Gregor Matthias Rack, Victor L. Rangel, Silvia Russi, Rachael E. Skyner, Clyde A. Smith, Alexei S. Soares, Jennifer L. Wierman, Kang Zhu, Peter O’Brien, Natalia Jura, Alan Ashworth, John J. Irwin, Michael C. Thompson, Jason E. Gestwicki, Frank von Delft, Brian K. Shoichet, James S. Fraser, Ivan Ahel.

Further information online

Digital Edition

Lab Asia 29.4 - August 2022

August 2022

In This Edition Chromatography - Automated Sample Preparation:The Missing Hyphen to Hypernation - New Low Volume Air Sampler for PFAS Analysis - Analytical Intelligence Starts with the Samp...

View all digital editions


ACS National Meeting & Expo, Fall 2022

Aug 21 2022 Chicago, IL, USA & Online


Aug 22 2022 Frankfurt, Germany

IMSC 2022

Aug 27 2022 Maastricht, Netherlands

EuCheMS Chemistry Congress

Aug 28 2022 Lisbon, Portugal

Medical Fair Asia 2022

Aug 31 2022 Singapore

View all events